FCGRT and myotonic dystrophy type 1: The current era of genomic medicine appears to provide unprecedented opportunity to further delineate the pathophysiology of this entity, for example by assessing differences between patients with DM1 with and without low IgG in terms of FcRn and IgG RNA and potential regulator or intermediaries [9] between FcRn and IgG.